Subjects who have a positive serum human chorionic gonadotropin (hCG), are pregnant or lactating are ineligible
Pregnant or nursing (lactating) women, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (>  mIU/mL); pregnancy is ruled out by a beta hCG test completed if necessary with an ultrasound
Females who are pregnant (beta-human chorionic gonadotropin positive [beta-HCG+]) or breast-feeding
Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin [B-hCG] pregnancy test)
DONOR: females who are pregnant (positive serum beta-human chorionic gonadotropin [B-HCG]) or uninterruptible breastfeeding
Female subjects who are nursing or pregnant (positive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test) at screening or pre-dose on day 
Performed within  business days of treatment initiation with the exception of beta-human chorionic gonadotropin (HCG) ( hours), if applicable: Absolute neutrophil count (ANC) >=  /uL.
Pregnant or breastfeeding women who do not consent to stop breast-feeding while on study treatment and for  days after the use of the investigational vaccine where pregnancy is confirmed by a positive, rising human chorionic gonadotropin (hCG) laboratory test
Female patients who are pregnant (positive beta-HCG) or breastfeeding.
Female patients who are pregnant confirmed by beta human chorionic gonadotropin (bHCG) laboratory (lab) test
Female subjects who are nursing or pregnant (positive serum or urine Beta-human chorionic gonadotropin [B-hCG] pregnancy test)
Normal beta-human chorionic gonadotropin (HCG) (per the local laboratory assay) within  days of RPLND
Subject is pregnant or nursing; serum or urine beta-human chorionic gonadotropin (HCG) must be checked in all non-postmenopausal patients or patients of childbearing potential
WOCBP who have a positive beta-human chorionic gonadotropin (hCG) test or are breastfeeding
Female patients who are diagnosed as pregnant by beta human chorionic gonadotropin (hCG) testing (per institutional practice) or breast-feeding
Female patients who are pregnant (positive beta-human chorionic gonadotropin [B-HCG]) or breastfeeding
Pregnant or nursing (to be confirmed with quantitative human chorionic gonadotropin [HCG] testing)
Pregnant or need to breast feed during the study period (negative beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for  weeks after the last dose of nivolumab
DONOR:\r\n* Donors will be excluded if they are an identical twin of the recipient\r\n* Females who are pregnant (positive serum beta human chorionic gonadotropin beta [? HCG]) or uninterruptible breastfeeding\r\n* HIV seropositive\r\n* Donors receiving experimental therapy or investigational agents unless approved by the protocol chair
Negative serum beta-human chorionic gonadotropin (HCG)
Subject is pregnant, has a positive serum human chorionic gonadotropin (hCG) or is lactating
Subjects who are pregnant, have a positive serum human chorionic gonadotropin (hCG) or are lactating
Female patients of childbearing age are excluded if they are pregnant as determined with a serum beta HCG no greater than  days prior to study registration, or breast-feeding. (The exclusion is made because gadolinium may be teratogenic in pregnancy).
Beta human chorionic gonadotropin (beta HCG) negative
Female patients who are pregnant (positive beta-human chorionic gonadotropin [b-HCG]) or breast feeding.
Pregnant women are excluded from this study, where pregnancy is confirmed by a positive serum beta-human chorionic gonadotropin (hCG) laboratory test; breast-feeding should be discontinued
Female patients who are pregnant (positive b-human chorionic gonadotropin [HCG]) or breastfeeding
Female patients who are pregnant (positive beta-human chorionic gonadotropin [HCG]) or breastfeeding will be excluded from study entry; sexually active men and women must use contraceptive techniques during and for  weeks following completion of maintenance therapy
The patient is pregnant (confirmed by serum beta human chorionic gonadotropin [b-HCG], if applicable) or is breastfeeding
Pregnant (i.e., positive beta-human chorionic gonadotropin test) or lactating
Is pregnant (confirmed by beta human chorionic gonadotrophin [?-HCG]) or lactating.
Patient is pregnant (confirmed by serum beta- b-human chorionic gonadotropin [HCG] if applicable) or is breastfeeding
HAPLO-IDENTICAL DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study
DONOR: Pregnancy (positive serum or urine beta-human chorionic gonadotropin [b-HCG]) or breastfeeding; women of childbearing age must avoid becoming pregnant while on the study
Pregnant women with a positive (blood beta-human chorionic gonadotropin [B-HCG]) pregnancy test are excluded from this study
Females must not be pregnant (negative human chorionic gonadotropin test within  hours prior to receiving the first dose of study medication) or breastfeeding
Pregnant females as determined by positive human chorionic gonadotropin (hCG) test at screening or prior to dosing.
Female subjects must not be pregnant as documented by a negative beta-human chorionic gonadotropin (beta-hCG) test with a minimum sensitivity  IU/L or equivalent unit of beta-hCG at Screening and Baseline, or breastfeeding.
Pregnancy (positive serum beta human chorionic gonadotropin [b-HCG]) or breastfeeding
Pregnant or breast-feeding; pre-menopausal patients must have a negative serum human chorionic gonadotropin (HCG) within  days of enrollment
Pregnant (i.e., positive beta-human chorionic gonadotropin [HCG]) or breast feeding
Women who are pregnant or post-partum (within  months of delivery); patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator; pregnancy testing is not required per protocol to determine study eligibility; women who become pregnant on the ISDO arm via reproductive technology can remain on study; however, data collection will be suspended during pregnancy and  months post-partum
Pregnant or need to breast feed during the study period (negative urine beta-human chorionic gonadotropin [HCG] test required), or unable to maintain use of contraception while on study and for  month after the last dose of AED
Women who are pregnant; patients are deemed not pregnant by virtue of urine pregnancy test (UPT), transvaginal ultrasound, beta human chorionic gonadotropin (HCG), or best judgement of the investigator, pregnancy testing is not required per protocol to determine study eligibility
Female patient who is pregnant or lactating (the possibility of pregnancy has to be excluded by negative serum or urine beta-human chorionic gonadotropin [?-HCG] results, obtained within  hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of  year without menses)
Any woman who is pregnant or has reason to believe she is pregnant or any woman who is lactating (the possibility of pregnancy has to be excluded by negative urine beta-human chorionic gonadotropin [beta-HCG] results, obtained within  hours before the perflutren lipid administration, or on the basis of patient history, e.g.: tubal ligation, hysterectomy or a minimum of  year without menses)
Pregnant women and women who are breast feeding will be excluded from this study; (the Vanderbilt University Medical Center radiology MRI Procedure Screening Form will be used to identify and exclude subjects who are pregnant or breastfeeding; a urine pregnancy test/or serum beta human chorionic gonadotropin [HCG] will also be performed for each pre-menopausal subject)
The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding
The participant, if female, is pregnant (confirmed by serum or urine beta-human chorionic gonadotropin [?-HCG] pregnancy test) or breastfeeding